Follicular lymphoma is a diverse disease, both biologically and clinically. Patients may present with indolent, asymptomatic disease or more aggressive, symptomatic disease with high tumor burden.

Panelists discuss key factors in deciding between monotherapy and combination approaches for bispecific therapies in follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) as well as the ...

Healio spoke with Paolo Caimi, MD, a physician and clinical investigator at Cleveland Clinic, about results from the inMind ...

Axicabtagene ciloleucel had durable responses, long-term survival, and consistent outcomes in patients with relapsed or ...

IFLI has a proven track record of advancing lymphoma treatments through strategic funding and collaborative partnerships, including its support for groundbreaking research at Washington University in ...

A panelist discusses how various antibody-drug conjugates, including polatuzumab vedotin, pinatuzumab vedotin, and ...

CMN-005 is under clinical development by Benecyte and currently in Phase II for Follicular Lymphoma. According to GlobalData, Phase II drugs for Follicular Lymphoma have a 43% phase transition success ...

CTX-131 is under clinical development by CRISPR Therapeutics and currently in Phase II for Follicular Lymphoma.